Global Brain Tumor Drugs Market Size To Worth USD 4.65 Billion By 2033 | CAGR of 10.14%

Global Brain Tumor Drugs Market Size To Worth USD 4.65 Billion by 2033

According to a research report published by Spherical Insights & Consulting, The Global Brain Tumor Drugs Market Size is Expected to Grow from USD 1.77 Billion in 2023 to USD 4.65 Billion by 2033, at a CAGR of 10.14% during the forecast period 2023-2033.   

Browse key industry insights spread across 255 pages with 110 Market data tables and figures & charts from the report on the "Global Brain Tumor Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drugs (Bevacizumab, Temozolomide, and Others), By End-User (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/brain-tumor-drugs-market

The brain tumor drug market focuses on discovering, manufacturing, and distributing drugs like carmustine, cisplatin, methotrexate, and temozolomide for treating brain tumors. Primary and secondary brain tumors originate in brain tissue, and one in every 100 US cancers spreads to the skull. Government initiatives, such as improved cancer treatment access and expanded medical education, drive demand. The increasing number of neurological disorders in children and adults also contributes to the growth of the brain tumor drug market. The brain tumor drug market is expanding due to neurological disorders, longer life expectancy, increased infection exposure, and sedentary lifestyles. Technological advancements, clinical trials, and regulatory support are driving growth, with collaboration between healthcare institutions and pharmaceutical companies fostering novel treatments. However, the high cost of drugs may impede the brain tumor drugs market.

The temozolomide segment accounted for the highest growth rate of 13.28% in 2023.

Based on the product, the global brain tumor drugs market is categorized as bevacizumab, temozolomide, and others. Among these, the temozolomide segment accounted for the highest growth rate of 13.28% in 2023. Temozolomide, a stable, first-line drug, enhances patient survival, bioavailability, and blood-brain barrier permeability, showing therapeutic activity against malignant glioma by binding to DNA and interfering with cell growth and division.

The hospital pharmacy segment dominated the market with 56.89% of the share in 2023 and is anticipated to grow at a substantial CAGR throughout the projected timeframe.

Based on the end-user, the global brain tumor drugs market is categorized as retail pharmacy, hospital pharmacy, and online pharmacy. Among these, the hospital pharmacy segment dominated the market with 56.89% of the share in 2023 and is anticipated to grow at a substantial CAGR throughout the projected timeframe. The growth of the segment is attributed to the complexity of brain tumor treatment, frequent patient monitoring, daily blood checkups, accurate diagnosis, and easy access to healthcare professionals.

North America is expected to hold the greatest share of the global brain tumor drugs market over the forecast period.

North America is expected to hold the greatest share of the global brain tumor drugs market over the forecast period. North America's brain tumor drugs market growth is driven by drug discoveries, increased cancer awareness, advanced healthcare, government schemes, fitness clubs, and advanced diagnostic devices.

Asia Pacific is predicted to hold the fastest-growing region of the global brain tumor drugs market throughout the estimated period. The Asia-Pacific region is experiencing a surge in demand for brain tumor treatment options owing to rising chronic diseases with India leading the way and China dominating the market.

Major key players in the global brain tumor drugs market are Emcure Pharmaceuticals Limited, Novartis Oncology, Astellas Pharma Inc., AstraZeneca plc., GlaxoSmithKline plc, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Novo Nordisk A/S, Euro lab, Aspen, Neopharma, Baxter International Inc., Bristol Myers Squib, Celnova Pharma, Sanofi, Kitov Pharma Limited, Sandoz AG, Julphar, AIDS Genomic Limited, and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In February 2025, The Australian Government invested USD 20 million in research to support children, adolescents, and young adults with childhood brain cancers, including DIPG. Three universities applied for funding through the Medical Research Future Fund 2024 Paediatric Brain Cancer Research Grants.

• In June 2024, Scientists from Northwestern Medicine developed ultrasound technology for the treatment of glioblastoma. This novel technology penetrates the blood-brain barrier and provides a small dose of a chemotherapy drug cocktail. Scientists utilized doxorubicin in combination with immune checkpoint antibodies to enhance the immune system's recognition of malignant glioblastoma cells and reactivate lymphocytes for cancer cell attack.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global brain tumor drugs market based on the below-mentioned segments:

Global Brain Tumor Drugs Market, By Drugs

• Bevacizumab
• Temozolomide
• Others

Global Brain Tumor Drugs Market, By End-User

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Global Brain Tumor Drugs Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter